Multidisciplinary Approach ⁢Key to Advanced cSCC‌ Treatment

⁣ Updated June 10,⁢ 2025

Managing ⁣advanced cutaneous squamous cell carcinoma (cSCC)⁤ requires a coordinated, multidisciplinary approach, according to Dr.​ Martin dietrich, ⁢a medical oncologist‌ at Cancer Care Centers of Brevard. Dietrich emphasized the importance of ‌integrating medical oncology ​with surgical and radiation oncology, especially for‌ cases extending beyond surgical solutions.

Dietrich highlighted that ⁢his role focuses on cutaneous malignancies,including melanoma,squamous cell carcinomas,and basal cell carcinomas. He noted that systemic therapy is often necesary for metastatic diseases, complementing local interventions. Challenging cases, he said, frequently enough involve multiple specialties,‍ requiring coordinated care from dermatology,⁤ Mohs surgery, radiation, ENT, and plastic reconstruction ‌surgery.

High-risk ‌cSCC, dietrich‍ explained, is defined by clinical and pathological features that increase⁤ the risk of recurrence or metastasis. ​Factors such as tumor size, location, and poorly differentiated histology are critical. He added‍ that high-grade tumors, lymph node ‌spread, and perineural invasion also raise concerns.⁣ Prior treatments can further influence ‌risk assessment.

When determining the need for systemic ‌therapy, Dietrich said multidisciplinary teams aim for ⁣durable control and optimal functional and cosmetic⁤ outcomes.‌ He‌ stressed⁤ the importance ⁣of considering the psychosocial ​impacts of cSCC, including anxiety and ​depression.The availability of‌ effective ‍systemic therapies should prioritize patient-centered care and improved medical oncology ​outcomes.

For unresectable cSCC, systemic therapy selection depends on the disease setting and patient-specific factors. While ​radiosensitizing chemotherapy may be used with‌ radiation, immunotherapy with PD-1 inhibitors is now the standard first-line treatment, Dietrich‍ noted. ​He mentioned promising data ⁢with injectable oncolytic ​viruses that enhance local inflammatory effects and synergize with checkpoint inhibitors. ⁢These therapies are also being explored for solid-organ transplant recipients.

Checkpoint inhibitors are generally‍ well-tolerated, and management protocols are well-established, Dietrich said. He emphasized ⁣that patient and ​provider education is crucial for safe delivery. Monitoring strategies include symptom questionnaires, nurse triage, regular lab tests, ‌and clinic visits. With extensive experience, ⁣clinicians have confidence in thier favorable risk-benefit profile.

Ideally, medical, surgical,⁣ and ⁣radiation oncology‍ teams should collaborate from the initial diagnosis, Dietrich stated. Early collaboration optimizes oncologic, functional, and cosmetic⁤ outcomes and prevents ‌recurrence. Unluckily, referrals are often sequential, delaying optimal care and limiting systemic therapy effectiveness. ‍Early integration‌ of ⁤medical oncology is critical⁢ for the ⁤best outcomes.

Multidisciplinary collaboration is often built‍ on close, real-time interaction, Dietrich explained. Sharing images ​and clinical impressions enhances​ efficiency and supports timely ​care planning. Strong relationships with dermatologists ‌are fostered thru outreach⁣ and ​education,‍ complementing surgical interventions ‌with systemic therapy when‍ appropriate.

Effective multidisciplinary care‌ depends on ⁤intentional coordination, Dietrich said. Consulting with ⁣surgical and radiation colleagues⁢ ensures ‌alignment⁤ on treatment goals and patient-centered decisions. Real-time communication⁤ and shared medical records foster continuity,transparency,and a unified standard of care.

Dietrich noted that communication gaps often stem ⁢from logistical barriers. direct, personal lines ⁣of communication are essential. Proactive ⁣outreach‍ to dermatologists and their staff helps ensure patients receive ⁤the⁢ necessary multidisciplinary care without delays.

“Early‌ integration of⁤ medical oncology into the treatment⁤ plan is critical for the‍ best outcomes,” Dietrich⁢ said.

What’s next

Looking ahead, dietrich envisions medical oncologists playing an increasingly central role‌ in managing cSCC. emerging‍ therapies, like⁣ injectable ​oncolytic viruses, will enhance⁤ treatment options. Early involvement​ of medical oncologists, even before surgery, can improve resectability and outcomes through neoadjuvant immunotherapy. The focus⁢ remains on expanding access ⁤to these advances and refining strategies to benefit more patients with advanced cutaneous squamous cell carcinoma.